Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Heiny, A T ^a   Miotto, Olivo ^a,b   Srinivasan, Kellathur N ^c,d   Khan, Asif M ^a   Zhang, G L ^e   Brusic, Vladimir ^f   Tan, Tin Wee ^a   August, J Thomas ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HEALTH SCIENCES AUTHORITY   (Singapore)

^e INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE; EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INFLUENZA VACCINE; MATRIX PROTEIN; NUCLEOPROTEIN; PARAINFLUENZA VACCINE; VIRUS ENZYME; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; DNA SEQUENCE; GENETIC ALGORITHM; GENETIC CONSERVATION; GENETIC DATABASE; GENETIC VARIABILITY; INFLUENZA VIRUS A; PREDICTION; PROTEIN DATABASE; PROTEIN DETERMINATION; PROTEIN TARGETING; RNA SEQUENCE; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS STRAIN; ANIMAL; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR EVOLUTION;

ANIMALIA; AVES; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS;

ANIMALS; EPITOPES; EVOLUTION, MOLECULAR; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; T-LYMPHOCYTES; VIRAL PROTEINS;

EID: 43149084860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001190     Document Type: Article

References (93)

1. De Jong JC, Rimmelzwaan GF, Fouchier RA, Osterhaus AD (2000) Influenza virus: a master of metamorphosis. J Infect 40: 218-228.
2. Treanor J (2004) Weathering the influenza vaccine crisis. N Engl J Med 351: 2037-2040.
3. Kilbourne ED (2006) Influenza pandemics of the 20th century. Emerg Infect Dis 12: 9-14.
4. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437: 1162-1166.
5. Obenauer JC, Denson J, Mehta PK, Su X, Mukatira S, et al. (2006) Large-scale sequence analysis of avian influenza isolates. Science 311: 1576-1580.
6. Lambkin R, Novelli P, Oxford J, Gelder C (2004) Human genetics and responses to influenza vaccination: clinical implications. Am J Pharmacogenomics 4: 293-298.
7. Subbarao K, Murphy BR, Fauci AS (2006) Development of effective vaccines against pandemic influenza. Immunity 24: 5-9.
8. Uscher-Pines L, Omer SB, Barnett DJ, Burke TA, Balicer RD (2006) Priority setting for pandemic influenza: an analysis of national preparedness plans. PloS Med 3: e436.
9. Benacerraf B (1978) A hypothesis to relate the specificity of T lymphocytes and the activity of I region-specific Ir genes in macrophages and B lymphocytes. J Immunol 120: 1809-1812.
10. Townsend AR, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42: 457-467.
11. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, et al. (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329: 512-518.
12. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76: 287-299.
13. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA (2005) Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immumol Rev 207: 145-157.
14. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23: 975-1028.
15. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296.
16. van Bleek GM, Nathenson SG (1991) The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides. Proc Natl Acad Sci U S A 88: 11032-11036.
17. Engelhard VH (1994) Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12: 181-207.
18. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
19. Hammer J, Valsasnini P, Tolba Y, Bolin D, Higelin J, et al. (1993) Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197-203.
20. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, et al. (1995) Several HLA alleles share overlapping peptide specificities. J Immunol 154: 247-259.
21. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212.
22. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, et al. (2004) Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55: 797-810.
23. Doytchinova IA, Flower DR (2005) In silico identification of supertypes for class II MHCs. J Immunol 174: 7085-7095.
24. Bian H, Hammer J (2004) Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34: 468-475.
25. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 35: 2295-303.
26. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V (2005) MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res 33(Web Server issue): W172-179.
27. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, et al. (2005) Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57: 304-314.
28. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 171: 5611-5623.
29. Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
30. Brusic V, August JT (2004). The changing field of vaccine development in the genomics era. Pharmacogenomics 5: 597-600.
31. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
32. Klavinskis LS, Whitton JL, Oldstone MB (1989) Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol 63: 4311-4316.
33. Castrucci MR, Hou S, Doherty PC, Kawaoka Y (1994) Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol 68: 3486-3490.
34. Stemmer C, Quesnel A, Prevost-Blondel A, Zimmermann C, Muller S, et al. (1999) Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restrictcd CD8(+) T cell epitope GP33. J Biol Chem 274: 5550-5556.
35. Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, et al. (1998) Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 72: 6907-6910.
36. CD8= -T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 77: 11859-11866.
37. Del Val M, Schlicht HJ, Volkmer H, Messerle M, Reddehase MJ, et al. (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65: 3641-3646.
38. La Posta VJ, Auperin DD, Kamin-Lewis R, Cole CA (1993) Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol 67: 3497-3506.
39. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, et al. (1996) Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 157; 3039-3045.
40. Blaney JE Jr, Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, et al. (1998) Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 72: 9567-9574.
41. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, et al. (1995) Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 25: 2638-2642.
42. CD8= T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med 175: 1531-1538.
43. Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, et al. (2003) The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 309: 320-329.
44. CD8= T-cell peptide epitope of vaccinia and variola viruses. J Virol 78: 7052-7060.
45. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2007) HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J Virol 81: 2307-2317.
46. Hanke T, McMichael AJ, Dorrell L (2007) Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88: 1-12.
47. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, et al. (2004) Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 189: 2213-2219.
48. McMichael AJ, Gotch FM (1989) Recognition of influenza A virus by human cytotoxic T lymphocytes. Adv Exp Med Biol 257: 109-114.
49. Townsend AR (1987) Recognition of influenza virus proteins by cytotoxic T lymphocytes. Immunol Res 6: 80-100.
50. Askonas BA, Taylor PM, Esquivel F (1988) Cytotoxic T cells in influenza infection. Ann N Y Acad Sci 532: 230-237.
51. Lamb JR, McMichael AJ, Rothbard JB (1987) T-cell recognition of influenza viral antigens. Hum Immunol 19: 79-89.
52. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006) CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211: 8-22.
53. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
54. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
55. CD8= T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648-5653.
56. Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, et al. (1999) Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 162: 4163-4170.
57. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796-801.
58. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
59. Fomsgaard A, Nielsen HV, Kirkby N, Bryder K, Corbet S, et al. (1999) Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. Vaccine 18: 681-691.
60. Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR (1994) Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 68: 3505-3511.
61. CD8= cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 188: 223-232.
62. Crowe SR, Miller SC, Woodland DL (2006) Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24: 452-456.
63. Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, et al. (2007) A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol 244: 141-147.
64. Miotto O, Tan TW, Brusic V (2007) Rule-based Knowledge Aggregation for large-Scale Protein Sequence Analysis of Influenza A Viruses. BMC Bioinformatics, 8 Suppl 10: S7.
65. Cox NJ, Neumann G, Donis RO, Kawaoka Y (2005) Orthomyxoviruses: influenza In: Mahy BH, ter Meulen V, eds. Topley and Wilson's Microbiology and Microbial Infections, 10th Edition, Virology Volume 1, Chapter 32.
66. Edgar RC (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5: 113.
67. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-2822.
68. Shannon CE (1948) A mathematical theory of communication. Bell System Technical Journal 27: 379-423 and 623-656.
69. Rammensee HG (1995) Chemistry of peptides associated with MHO class I and class II molecules. Curr Opin Immunol 7: 85-96.
70. Paninski L (2003) Estimation of entropy and mutual information. Neural Computation 15: 1191-1253.
71. Peters B, Sidney J, Bourne P, Bui HH, Buus S, et al. (2005) The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 3: e91.
72. Peters B, Bui HH, Frankild S, Nielson M, Lundegaard C, et al. (2006) A community resource benchmarking predictions of peptide binding to MHC-1 molecules. PLoS Comput Biol 2: e65.
73. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, et al. (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nat Med. 7(12): 1306-1312.
74. Coleman JR (2007) The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages. Virol J. 4: 9.
75. Miotto O, Heiny AT, Tan TW, August JT, Brusic V (2007) Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by largescale mutual information analysis. BMC Bioinformatics, 8 Suppl 10: S18.
76. Mazumder R, Hu ZZ, Vinayaka CR, Sagripanti JL, Frost SD, et al. (2007) Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes. 35: 175-186.
77. Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, et al. (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol. 3: e751.
78. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13: 100-106.
79. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, et al. (2005) HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine. 23: 2136-2148.
80. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 171: 5611-5623.
81. Corbet S, Nielsen HV, Vinner L, Lauemoller S, Therrien D, et al. (2003) Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. The Journal of general virology 84: 2409-2421.
82. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. Journal of immunology (Baltimore, Md: 1950) 171: 5611-5623.
83. Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, et al. (2005) Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. The Journal of infectious diseases 192: 749-759.
84. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. Journal of virology 76: 8757-8768.
85. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, et al. (2004) Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. Journal of virology 78: 7069-7078.
86. Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, et al. (2004) Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. Journal of virology 78: 1324-1332.
87. Ferguson NM, Galvani AP, Bush RM (2003) Ecological and immunological determinants of influenza evolution. Nature 422: 428-433.
88. van Stipdonk MJ, Lemmens EE, Schoenberger SP (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2: 423-429.
89. CD8= T cells after acute infection. Nature immunology 5: 927-933.
90. CD8= T cell response. The Journal of experimental medicine 203: 2135-2143.
91. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (New York, NY) 300: 339-342.
92. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8 = T lymphocytes. Nature 421: 852-856.
93. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (New York, NY) 300: 337-339.